Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and gleason score in men with clinically localized prostate cancer
- 1 January 1994
- journal article
- clinical trial
- Published by Elsevier BV in International Journal of Radiation Oncology*Biology*Physics
- Vol. 28 (1), 33-37
- https://doi.org/10.1016/0360-3016(94)90138-4
Abstract
No abstract availableThis publication has 25 references indexed in Scilit:
- Prostate Specific Antigen in Patients with Clinical Stage C Prostate Cancer: Relation to Lymph Node status and GradeJournal of Urology, 1991
- Prognostic Significance of Lymph Nodal Metastases in Prostate CancerJournal of Urology, 1989
- Elective pelvic irradiation in stage A2, B carcinoma of the prostate: analysis of RTOG 77-06International Journal of Radiation Oncology*Biology*Physics, 1988
- Current conflicts in the management of prostatic cancerInternational Journal of Radiation Oncology*Biology*Physics, 1986
- Staging Errors in Clinically Localized Prostatic CancerJournal of Urology, 1982
- The incidence and extent of pelvic lymph node metastases in apparently localized prostatic cancerCancer, 1981
- Staging Pelvic Lymphadenectomy for Carcinoma of the Prostate: Risk Versus BenefitJournal of Urology, 1980
- Pelvic Lymphadenectomy for Staging Prostatic Carcinoma: Is it Always Necessary?Journal of Urology, 1979
- Differences in Pathological Characteristics and Prognosis of Clinical A2 Prostatic Cancer from A1 and B DiseaseJournal of Urology, 1978
- Prediction of Prognosis for Prostatic Adenocarcinoma by Combined Histological Grading and Clinical StagingJournal of Urology, 1974